[1] TORRE L A,BRAY F,SIEGEL R L,et al.Global cancer statistics,2012[J].CA Cancer J Clin,2015,65(2):87-108.
[2] 陈万青,郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床,2015,42(13):668-674.
[3] SIMMONS C E,HOGEVEEN S,LEONARD R,et al.A Canadian national expert consensus on neoadjuvant therapy for breast cancer:linking practice to evidence and beyond[J].Curr Oncol,2015,22(Suppl 1):S43-53.
[4] GIANNI L,PIENKOWSKI T,YOUNG-HYUCKI M,et al.Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced,inflammatory,or early HER2-positive breast cancer (NeoSphere):a randomised multicentre,open-label,phase 2 trial[J].Lancet Oncol,2012,13(1):25-32.
[5] GIANNI L,EIERMANN W,SEMIGLAZOV V,et al.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone,in patients with HER2-positive locally advanced breast cancer (the NOAH trial):a randomised controlled superiority trial with a parallel HER2-negative cohort[J].Lancet,2010,375(9712):277-384.
[6] HOLMES D,COLFRY A,CZERNIECKI B,et al.Performance and practice guideline for the use of neoadjuvant systemic therapy in the management of breast cancer[J].Ann Surg Oncol,2015,22(10):3184-3190.
[7] 周如海,邬颖杰,吴猛,等.超声造影技术在乳腺癌新辅助化疗疗效评估中的应用价值[J].医学影像学杂志,2015,25(3):711-714.
[8] 常立功,周齐.彩色多普勒超声联合MRI对小乳腺癌的诊断[J].现代医学,2015,43(12):1566-1568.
[9] ASANO Y,KASHIWAGI S,ONODA N,et al.Clinical verification of sensitivity to preoperative chemotherapy in cases of androgen receptor-expressing positive breast cancer[J].Br J Cancer,2016,114(1):14-20.
[10] BOWEN M E,MONE M C,BUYS S S,et al.Surgical outcomes for mastectomy patients receiving neoadjuvant chemotherapy:a propensity-matched analysis[J].Ann Surg,2017,265(3):448-456.
[11] 盛洁,高洁, 钱朋飞.X线钼靶与高频彩超对早期乳腺癌诊断的对比研究[J].中国临床医学影像杂志,2012,23(3):206-208.
[12] CASTANEDA C A,FLORES R,ROJAS K,et al.Association between mammographic features and response to neoadjuvant chemotherapy in locally advanced breast carcinoma[J].Hematol Oncol Stem Cell Ther,2014,7(4):149-156.
[13] CHEN J H,BAHRI S,MEHTA R S,et al.Impact of factors affecting the residual tumor size diagnosed by MRI following neoadjuvant chemotherapy in comparison to pathology[J].J Surg Oncol,2014,109(2):158-167.
[14] 顾雅佳,冯晓源,邱龙华,等.DWI对局部进展期乳腺癌新辅助化疗疗效评价的初步研究[J].放射学实践,2007,22(7):1249-1255.
[15] 吴延春,许新堂.联合钼靶X线摄影、MRI动态增强及弥散加权成像对乳腺癌的诊断价值[J].现代医学,2016,44(10):1327-1332.
[16] SHERI A,SMITH I E,JOHNSTON S R,et al.Residual proliferative cancer burden to predict long-term outcome following neoadjuvant chemotherapy[J].Ann Oncol,2015,26(1):75-80.
[17] BOSSUYT V,PROVENZANO E,SYMMANS W F,et al.Recommendations for standardized pathological characterization of residual disease for neoadjuvant clinical trials of breast cancer by the BIG-NABCG collaboration[J].Ann Oncol,2015,26(7):1280-1291.
[18] BASELGA J,BRADBURY I,EIDTMANN H,et al.Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO):a randomised, open-label,multicentre,phase 3 trial[J].Lancet,2012,379(9816):633-640.
[19] GERDES J,LEMKE H,BAISCH H,et al.Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67[J].Immunol,1984,133(4):1710-1715.
[20] DAWOOD S.Triple-negative breast cancer[J].Drugs,2010,70(17):2247-2258.
[21] HOSTER E,ROSENWALD A,BERGER F,et al.Prognostic value of Ki-67 index,cytology,and growth pattern in mantle-cell lymphoma:results from randomized trials of the European mantle cell lymphoma network[J].J Clin Oncol,2016,34(12):1386-1394.
[22] 桑果,王本忠.乳腺癌新辅助化疗不同方案近期疗效观察及化疗前后Ki-67的表达变化[J].安徽医科大学学报,2011,46(11):1181-1184.
[23] 杨芳,于雁.肿瘤微环境——肿瘤转移的关键因素[J].中国肺癌杂志,2015,18(1):48-54.
[24] 徐熠琳,李军楠,刘雪静,等.乳腺血氧功能成像技术与超声及X线检查联合应用诊断乳腺癌的价值[J].山东医药,2016,26(4):16-18.
[25] ZHONG X,XIE G,ZHANG Z,et al.MiR-4653-3p and its target gene FRS2 are prognostic biomarkers for hormone receptor positive breast cancer patients receiving tamoxifen as adjuvant endocrine therapy[J].Oncotarget,2016,7(38):61166-61182.
[26] DING M,SUN X,ZHONG J,et al.Decreased miR-200a-3p is a key regulator of renal carcinoma growth and migration by directly targeting CBL[J].J Cell Biochem,2018,119(12):9974-9985.
[27] 何春波,宿菲,齐秀英,等.血清miR_34a表达水平预测乳腺癌新辅助化疗疗效[J].解剖科学进展,2017,23(8):467-470,474. |
